Antiviral activity of ASOs targeting SARS-CoV-2 entry factors <i>ACE2</i> and <i>TMPRSS2</i>.

(A) Illustration of SARS-CoV-2 infection pathway of target cells (left). ACE2 and TMPRSS2 ASO targeting regions (right). (B) Relative ACE2 and TMPRSS2 mRNA expression levels after various ASO treatments at 3 μM or 1 μM in H1437 cells with washout step. P values were calculated using two tailed unpaired t test by comparing to control (Ctrl). (C) SARS-CoV-2 bioassay indicating infectivity and viability of H1437 cells after incubation with various ACE2 and TMPRSS2 ASOs against WA1 strain. P values were calculated using two tailed unpaired t test by comparing to control (Ctrl). (D) Dose response curve of SARS-CoV-2 bioassay of ACE2 ASOs against WA1 strain in H1437 cells. Bottom, representative images of ACE2 ASO #1 at varying concentrations. P values were calculated using two tailed unpaired t test by comparing to control (Ctrl). (E) Selected ACE2 ASO active and inactive compounds against WA1 strain in H1437 cells. P values were calculated using two tailed unpaired t test by comparing to control (Ctrl). (F) Selected ACE2 ASO active and inactive compounds against B.1.1.7 strain in H1437 cells. P values were calculated using two tailed unpaired t test by comparing to control (Ctrl).